Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis.

Study:

A Two Arm Phase II Chemoprevention Trial In Adenomatous Polyposis Coli Patients

Rationale:

The use of celecoxib with or without eflornithine may be an effective way to prevent colorectal cancer in patients who have familial adenomatous polyposis.

Purpose:

Randomized phase II trial to compare the effectiveness of celecoxib with or without eflornithine in preventing colorectal cancer in patients who have familial adenomatous polyposis.

Study Status: Active, not recruiting

Recruiting:
n/a

Condition Intervention Phase
Colorectal Cancer
Precancerous Condition
Drug: Celecoxib
Drug: Eflornithine
Other: Placebo
Phase 2

Verified by National Cancer Institute (NCI) June, 2012

Sponsored by: National Cancer Institute (NCI)
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00033371

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States

Patrick M. Lynch, MD, JD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site